These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27984399)

  • 1. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy: A Prospective Longitudinal Cohort Study.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE
    J Clin Gastroenterol; 2018 Mar; 52(3):229-234. PubMed ID: 27984399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
    J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE
    Scand J Gastroenterol; 2016; 51(4):442-7. PubMed ID: 26595391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question.
    Monteiro S; Dias de Castro F; Leite S; Moreira MJ; Cotter J
    Scand J Gastroenterol; 2019 Jan; 54(1):49-54. PubMed ID: 30663515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
    Molander P; Färkkilä M; Ristimäki A; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
    J Crohns Colitis; 2015 Jan; 9(1):33-40. PubMed ID: 25052347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients.
    Foster AJ; Smyth M; Lakhani A; Jung B; Brant RF; Jacobson K
    World J Gastroenterol; 2019 Mar; 25(10):1266-1277. PubMed ID: 30886509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease.
    Naismith GD; Smith LA; Barry SJ; Munro JI; Laird S; Rankin K; Morris AJ; Winter JW; Gaya DR
    J Crohns Colitis; 2014 Sep; 8(9):1022-9. PubMed ID: 24566170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice.
    Pauwels RWM; de Vries AC; van der Woude CJ
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1893-1901. PubMed ID: 32291796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.
    Molander P; af Björkesten CG; Mustonen H; Haapamäki J; Vauhkonen M; Kolho KL; Färkkilä M; Sipponen T
    Inflamm Bowel Dis; 2012 Nov; 18(11):2011-7. PubMed ID: 22223566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.
    Diederen K; Hoekman DR; Leek A; Wolters VM; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Benninga MA; Kindermann A
    Aliment Pharmacol Ther; 2017 Apr; 45(7):951-960. PubMed ID: 28138990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
    Molander P; Färkkilä M; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
    Inflamm Bowel Dis; 2014 Jun; 20(6):1021-8. PubMed ID: 24798636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.
    Tursi A; Elisei W; Picchio M; Giorgetti G; Brandimarte G
    Dig Dis Sci; 2015 May; 60(5):1406-13. PubMed ID: 25445163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
    Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
    Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
    Boschetti G; Garnero P; Moussata D; Cuerq C; Préaudat C; Duclaux-Loras R; Mialon A; Drai J; Flourié B; Nancey S
    Inflamm Bowel Dis; 2015 Feb; 21(2):331-6. PubMed ID: 25625487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy.
    Bots SJ; Kuin S; Ponsioen CY; Gecse KB; Duijvestein M; D'Haens GR; Löwenberg M
    Scand J Gastroenterol; 2019 Mar; 54(3):281-288. PubMed ID: 30907185
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control.
    van Rheenen PF
    Inflamm Bowel Dis; 2012 Nov; 18(11):2018-25. PubMed ID: 22275341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.